Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Orthocell Ltd ( (AU:OCC) ) has shared an announcement.
Orthocell Ltd has announced significant changes to its Board of Directors, with the Hon Kim Beazley AC stepping down due to health reasons but continuing in an advisory role for US and Defence matters. Michael McNulty, with extensive leadership experience, joins as a Non-Executive Director and Chair of the Audit Committee, while Dr Ravi Thadhani is elevated to Lead Independent Director, focusing on US commercialization of Orthocell’s nerve repair product, Remplir™. These changes, alongside recent executive appointments, are part of Orthocell’s strategy to accelerate its global expansion and enhance its market positioning, particularly in the US.
The most recent analyst rating on (AU:OCC) stock is a Buy with a A$1.32 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Ltd is a regenerative medicine company focused on developing innovative solutions for tissue repair and regeneration. The company is particularly engaged in the commercialization of its flagship nerve repair product, Remplir™, with a strong emphasis on expanding its presence in the US healthcare market.
Average Trading Volume: 926,850
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$336.6M
Find detailed analytics on OCC stock on TipRanks’ Stock Analysis page.